证监许可【2011】1288号 报告 5月消费超预期 投资增速回落 2025年6月20日 更多精彩内容 请关注 格林大华期货 官方微信 研究员：刘洋 联系方式：liuyang18036@greendh.com 期货从业资格证号：F3063825 期货交易咨询号：Z0016580 国债期货一周行情复盘 本周国债期货主力合约总体表现为震荡上行，30年品种走势偏强，截至收盘全周30年国债涨0.71%，10年国债涨 0.14%，5年国债涨0.12%，2年国债涨0.09%。 数据来源：wind，格林大华 5月份家用电器和音像器材类、通讯器材类等同比涨幅较大 以旧换新政策推动下，5月限额以上单位家用电器和音像器材类、通讯器材类、文化办公用品类、家具类商品零 售额分别增长53.0%、33.0%、30.5%、25.6%，4月分别增长38.8%、19.9%、33.5%、26.9%。基本生活类和部分升 级类商品销售增势较好，限额以上单位粮油食品类、金银珠宝类、体育娱乐用品类商品零售额分别增长14.6%、 21.8%、28.3%，4月分别增长14.0%、25.3%、23.3%。5月份限额以上单位汽车类消费品零售总额同比增长1.1% ...

六安市开发区汪俊豪果品批发商行销售的香蕉，噻虫嗪不符合食品安全国家标准。检验机构为国检测试控股集团（安徽）拓维检测服务有限公司。 六安市裕安区徐集镇街道孔祥中销售的食荚豌豆（荷兰豆），噻虫胺不符合食品安全国家标准。检验机构为国检测试控股集团（安徽）拓维检测服务有限公 司。 霍邱县润沐商贸有限公司销售、标称合肥市百贝鲜食品有限公司生产的西瓜味吐司面包，霉菌不符合食品安全国家标准。检验机构为安徽中青检验检测有限 公司。 | 索 引 号: | /202506-00044 | 组配分类： | 食品抽检信息 | | --- | --- | --- | --- | | 发布机构： | 市市场监管局 | 主題分类： | 市场监督、安全生产监管 | | 成文日期： | 暫元 | 发文日期： | 2025-06-19 15:41 | | 文 号: | | 关键词: | | | 称: ਮ | 六安市市场监督管理局食品安全抽检信息通告 (2025年第28期) | | | 近期，六安市市场监督管理局组织抽检抽检食用农产品、粮食加工品、饮料、茶叶及相关制品、糕点5类食品88批次样品。根据食品安全国家标准、产品明 示标准和质量要求检验和 ...

Core Viewpoint - The company, Shandong Bangji Technology Co., Ltd., plans to issue shares and pay cash to acquire assets from Riverstone Farm Pte. Ltd., which includes 100% equity stakes in several pig farming companies and a partial stake in a consulting firm, aiming to vertically integrate its operations in the livestock industry [9][19]. Group 1: Transaction Overview - The transaction involves issuing shares and paying cash to acquire 100% equity in North Stream Animal Husbandry, Rui Dong Wei Li, Xin Mu Animal Husbandry, Rui Dong Animal Husbandry (Lijin), Rui Dong Animal Husbandry (Shandong), and Wei Li Animal Husbandry (Binzhou), as well as 80% equity in Pi Si Dong [9][19]. - The specific transaction price and the number of shares to be issued are yet to be determined, pending the completion of auditing and evaluation work [9][20]. Group 2: Impact on Business Operations - The acquisition will allow the company to extend its operations from solely producing pig feed to include pig farming and sales, creating a vertically integrated supply chain [19][20]. - The company specializes in the research, production, and sales of pig feed, with a focus on optimizing feed formulations and production processes to maintain high product quality [19][20]. Group 3: Financial Implications - The transaction is expected to enhance the company's asset scale, revenue, and net profit attributable to shareholders, thereby improving overall performance [20]. - The final financial impact will be assessed after the completion of the auditing and evaluation processes [20]. Group 4: Regulatory and Approval Process - The transaction requires approval from the shareholders' meeting and regulatory bodies, including the China Securities Regulatory Commission [3][20]. - The company has committed to strict compliance with information disclosure obligations and will ensure that the transaction pricing is fair and reasonable [25][26]. Group 5: Stakeholder Commitments - The controlling shareholder and senior management have pledged not to reduce their holdings during the transaction process, ensuring stability [22][23]. - The company will implement measures to protect the rights of minority investors throughout the transaction [26].

青岛华航环境科技有限责任公司，成立于2014年，位于青岛市，是一家以从事仪器仪表制造业为主的企 业。企业注册资本2215万人民币。通过天眼查大数据分析，青岛华航环境科技有限责任公司共对外投资 了1家企业，参与招投标项目151次，财产线索方面有商标信息3条，专利信息26条，此外企业还拥有行 政许可6个。 上海雷探科技有限公司，成立于2017年，位于上海市，是一家以从事科技推广和应用服务业为主的企 业。企业注册资本500万人民币。通过天眼查大数据分析，上海雷探科技有限公司参与招投标项目48 次，财产线索方面有商标信息3条，专利信息33条，此外企业还拥有行政许可2个。 来源：金融界 金融界2025年6月20日消息，国家知识产权局信息显示，中国长江三峡集团有限公司、上海勘测设计研 究院有限公司、青岛华航环境科技有限责任公司、上海雷探科技有限公司取得一项名为"一种海上风能 资源探测装置"的专利，授权公告号CN115523384B，申请日期为2022年10月。 天眼查资料显示，中国长江三峡集团有限公司，成立于1993年，位于武汉市，是一家以从事电力、热力 生产和供应业为主的企业。企业注册资本21150000万人民币。通过 ...

Group 1 - The company, TIDE Pharmaceutical (03880.HK), has launched an IPO, planning to issue 16.8 million shares globally, with 15.12 million shares for international offering and 1.68 million shares for public offering in Hong Kong [1] - The expected price range for each share is between HKD 28.40 and HKD 30.60, with estimated net proceeds from the global offering around HKD 411 million after deducting underwriting commissions and other expenses [1] - The funds raised will be used to expand service capacity and production in the US and China, increase capacity at the Qiantang Park, and build facilities in the Pharmaceutical Town [1] Group 2 - TIDE Pharmaceutical has entered cornerstone investment agreements with CSPC Pharmaceutical Group (01093.HK) and Welight Capital, with a total subscription amount of approximately USD 10 million [2] - In 2023, TIDE Pharmaceutical is the third largest global CRDMO focused on peptides, holding a market share of 1.5%, providing CRO and CDMO services primarily for API rather than finished drugs [2] - The company has established stable customer relationships in over 50 countries, with peptide drugs generally showing better tolerability, specificity, and bioactivity compared to chemical drugs [2] Group 3 - TIDE Pharmaceutical's revenue fluctuated from 2022 to 2024, with revenues of approximately RMB 351 million, RMB 337 million, and RMB 442 million, and net profits of approximately RMB 53.98 million, RMB 48.90 million, and RMB 59.17 million respectively [3] - In 2024, CDMO service revenue reached RMB 330 million, accounting for 74.6% of total revenue, with 55% of revenue coming from the US market, significantly higher than the 21.4% from the Chinese market [3] - The company indicated that recent US-China trade tensions may introduce uncertainties, but believes that new tariff policies will not have a direct or immediate significant impact on its business operations or financial performance [3]

"上午刚上传相关手续，下午不出工地就拿到施工许可证，这样的服务速度我们非常满意。"6月3 日，扬子泓远绿色高技术清洁能源船制造基地项目负责人杨伟文赞叹道。靖江市新桥镇依托重大项目三 方联办体系，灵活运用"容缺预审""超时默认制"等举措，全力推动扬子泓远项目施工许可证快速落地。 5月28日，劳氏船级社（中国）有限公司靖江分公司搬迁至靖江市港航贸中心。"选择入驻靖江港航 贸中心，是我们深耕中国市场的重要战略部署，以更好地就近服务客户。"公司首席验船师马琪说。靖 江市依托金融商务中心，重点打造港航贸中心，今年已有8家单位签订入驻协议。 完善"跨境出海"综合服务体系，帮助企业积极开拓新市场；优化土地供应机制，推行多元化土地供 应方式；密集举办产创融合、产学研对接活动……今年以来，靖江多部门协同发力，打出优化营商环 境"组合拳"。该市发布"千帆靖发"揭榜挂帅技术需求征集榜单，面向全球为14家企业征集16项关键技术 解决方案，总悬赏金额达2750万元，市科技部门将提供全流程跟踪服务与政策支持。 全程跟进，助企疏通"关键点" 5月25日，投资5.3亿元的恒睿达光伏电站组件生产项目在靖江城南园区开工。"我们选择在这里投 资， ...

Core Viewpoint - 泰德医药 plans to issue 16.8 million shares from June 20 to June 25, 2025, with a price range of HKD 28.4 to HKD 30.6 per share, aiming for listing on June 30, 2025 [1] Company Overview - 泰德医药 is the third largest global player in the peptide-focused CRDMO market, holding a market share of 1.5% as of 2023, providing full-cycle services from early discovery to commercial production [1][2] - The company primarily offers CRO services for peptide NCE discovery synthesis and CDMO services for peptide CMC development and commercial production [2] Market Position - The global peptide-focused CRDMO market is dominated by two major players with a combined market share of 23.8%, while the remaining participants, including 泰德医药, hold approximately 1% each [1] Client Relationships - 泰德医药 has established stable client relationships in over 50 countries, including major markets such as China, the US, Japan, Europe, South Korea, and Australia [2] Fundraising and Use of Proceeds - The estimated net proceeds from the global offering are approximately HKD 411 million, assuming a share price of HKD 29.50, with 76.4% allocated for facility expansion in the US and China [3] - 4.1% of the net proceeds will be used to expand capacity in China, while 9.5% will be for establishing sales and after-sales service networks in more regions [3] - 10.0% of the net proceeds will be allocated for working capital and other general corporate purposes [3] Cornerstone Investors - The company has signed cornerstone investment agreements, with cornerstone investors agreeing to subscribe for approximately 2.66 million shares, representing about 15.84% of the global offering [2]

Group 1 - The company, 泰德医药 (Tide Pharmaceutical), plans to globally offer 16.8 million H-shares, with 1.68 million shares available in Hong Kong and 15.12 million shares for international offering [1] - The subscription period for the shares is set from June 20 to June 25, 2025, with the expected pricing date on June 26, 2025, and trading on the Hong Kong Stock Exchange anticipated to start on June 30, 2025 [1] - The proposed price range for the shares is between HKD 28.40 and HKD 30.60, with a trading unit of 100 shares [1] Group 2 - According to Frost & Sullivan, the company is the third largest global player in the peptide-focused CRDMO market, holding a market share of 1.5% as of 2023 [2] - The company provides a full cycle of services from early discovery, preclinical research, clinical development to commercial production, primarily focusing on API rather than finished drugs [2] - The company has established stable customer relationships in over 50 countries, including major markets such as China, the USA, Japan, Europe, South Korea, and Australia [2] Group 3 - The company has signed cornerstone investment agreements, with cornerstone investors agreeing to subscribe for a total of 2.6608 million shares at a hypothetical price of HKD 29.50, amounting to approximately USD 10 million (around HKD 78.49 million) [3] - The estimated net proceeds from the global offering are approximately HKD 411.2 million, assuming a share price of HKD 29.50 [3] - The intended use of the net proceeds includes approximately 76.4% for expanding service capacity and production facilities in the USA and China, 4.1% for expanding capacity in China, 9.5% for establishing sales and after-sales service networks in more regions, and 10.0% for working capital and other general corporate purposes [3]

Core Viewpoint - The implementation of smart farms and the use of unmanned harvesting machines in Jiangsu's Zhenjiang City significantly enhance agricultural efficiency and productivity, addressing challenges posed by the region's hilly terrain [2][4]. Group 1: Smart Farm Implementation - The smart farm in Hezhuang Village utilizes three unmanned harvesting machines that can operate continuously, with each machine capable of harvesting approximately 200 acres in a 24-hour period, improving efficiency by over 70% compared to traditional methods [4][5]. - The introduction of smart farming technology aims to resolve issues related to labor shortages and agricultural productivity in hilly areas, where traditional farming yields are about half of those in flat regions [2][4]. Group 2: Technological Advancements - The unmanned harvesting machines are equipped with advanced features such as a navigation system, multiple cameras for situational awareness, and pressure sensors to monitor grain storage, allowing for automated operations and real-time adjustments [4][5]. - The use of AI technology in smart farming enables automatic identification of pest issues and crop growth monitoring, which has led to an increase in wheat yield from 500 pounds to over 1000 pounds per acre [5]. Group 3: Economic Impact - The cost savings from reduced labor needs—where one operator can manage multiple machines instead of three—result in a two-thirds reduction in labor costs [4][5]. - The expected return on investment for the initial setup of smart farming technology is projected to be achieved within four years due to increased efficiency and expanded operational capacity [5].

Core Viewpoint - In May, the industrial production in China showed a robust growth, with the industrial added value of large-scale enterprises increasing by 5.8% year-on-year, supported by the equipment manufacturing sector and stable growth in consumer goods manufacturing [1][2]. Group 1: Industrial Production Data - The industrial added value of large-scale enterprises grew by 5.8% year-on-year in May, with a month-on-month increase of 0.61% after seasonal adjustments [1]. - Manufacturing sector growth was recorded at 6.2%, surpassing the overall industrial growth by 0.4 percentage points [1]. - Among 41 major industries, 35 experienced year-on-year growth, resulting in a growth coverage of 85.4% [1]. Group 2: Equipment Manufacturing Sector - The added value of the equipment manufacturing sector increased by 9.0% year-on-year, contributing 54.3% to the overall industrial growth [2]. - The automotive industry saw a significant increase in added value by 11.6%, with a month-on-month acceleration of 2.4 percentage points [2]. - All eight sub-sectors within equipment manufacturing reported growth, with notable increases in railway, shipbuilding, aerospace, and electrical machinery sectors [2]. Group 3: High-end, Intelligent, and Green Manufacturing - High-tech manufacturing added value rose by 8.6% year-on-year, contributing 1.4 percentage points to overall industrial growth [3]. - Key products in high-end manufacturing, such as aircraft and industrial control systems, saw substantial growth rates of 18.7% and 15.5% respectively [3]. - The digital economy's integration into industrial production is increasing, with digital product manufacturing growing by 9.1% [3]. Group 4: Green Transformation and New Energy Products - The demand for new energy products and green materials is expanding, with the production of new energy vehicles and lithium-ion batteries increasing by 31.7% and 52.5% respectively [4]. - The supply of green products is also on the rise, with high-performance chemical fibers and bio-based chemical fibers seeing production increases of 92.2% and 21.5% [4]. Group 5: Policy Impact and Economic Recovery - The "two new" policy effects are positively influencing industrial production, with significant growth in sectors like motor manufacturing and shipbuilding [5]. - The automotive sector benefited from vehicle replacement subsidies, leading to an 11.3% increase in production [6]. - Overall, the manufacturing purchasing managers' index rose by 0.5 percentage points, indicating improved business expectations [6].